Moderna, Inc. (NASDAQ:MRNA) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lessened its holdings in Moderna, Inc. (NASDAQ:MRNA) by 17.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,999 shares of the company’s stock after selling 7,236 shares during the period. PNC Financial Services Group Inc.’s holdings in Moderna were worth $2,272,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. International Assets Investment Management LLC raised its holdings in Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after acquiring an additional 316,552 shares in the last quarter. State of Michigan Retirement System raised its holdings in shares of Moderna by 201.9% in the 2nd quarter. State of Michigan Retirement System now owns 274,248 shares of the company’s stock valued at $32,567,000 after purchasing an additional 183,407 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Moderna by 11.6% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company’s stock worth $107,885,000 after purchasing an additional 167,596 shares during the last quarter. Van ECK Associates Corp grew its stake in shares of Moderna by 75.4% during the third quarter. Van ECK Associates Corp now owns 266,929 shares of the company’s stock worth $17,839,000 after purchasing an additional 114,769 shares in the last quarter. Finally, Meitav Investment House Ltd. increased its holdings in Moderna by 96.6% in the third quarter. Meitav Investment House Ltd. now owns 226,903 shares of the company’s stock valued at $15,164,000 after buying an additional 111,475 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently issued reports on MRNA. Wolfe Research began coverage on Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a report on Thursday, September 19th. Barclays cut their price objective on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Hsbc Global Res upgraded shares of Moderna from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Finally, UBS Group cut their price target on shares of Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $84.00.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 2,930 shares of company stock worth $217,170 over the last three months. 15.20% of the stock is currently owned by corporate insiders.

Moderna Stock Up 6.2 %

Shares of Moderna stock opened at $43.66 on Tuesday. The company has a market cap of $16.80 billion, a P/E ratio of -7.50 and a beta of 1.69. The firm has a fifty day moving average of $54.96 and a two-hundred day moving average of $93.71. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. Moderna, Inc. has a one year low of $35.80 and a one year high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same quarter last year, the firm earned ($1.39) earnings per share. The firm’s revenue was up 3.8% compared to the same quarter last year. On average, analysts forecast that Moderna, Inc. will post -9.44 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.